HCC366 Cells

HCC366 is a human lung adenosquamous carcinoma cell line established from the malignant pleural effusion of an 80-year-old European female patient at the Hamon Cancer Center, UT Southwestern Medical Center. Adenosquamous carcinoma is a rare mixed histological subtype of non-small cell lung cancer (NSCLC) combining features of both adenocarcinoma and squamous cell carcinoma. HCC366 is is included in the Cancer Dependency Map (DepMap), CCLE, COSMIC cell lines, and MD Anderson Cell Lines Project panels. The line carries a homozygous TP53 p.Tyr220Cys mutation (a structural mutation of the DNA-binding domain) and a heterozygous ATM p.Pro534Ala mutation. It does not carry KRAS, EGFR, or STK11 driver mutations, and exhibits microsatellite stability (MSS). The doubling time is approximately 60–70 hours.
HCC366 is applicable in NSCLC research, particularly in studies of lung adenosquamous carcinoma biology, which remains understudied relative to pure adenocarcinoma or squamous cell carcinoma subtypes. Key applications include: TP53 gain-of-function mutation studies; ATM-mediated DNA damage response; chemotherapy sensitivity and resistance testing (cisplatin, paclitaxel, gemcitabine); evaluation of targeted agents; drug sensitivity profiling within DepMap and CCLE frameworks; biomarker discovery for mixed histology NSCLC; comparative genomics; and proteomic/transcriptomic profiling. HCC366 has also contributed to studies of lung cancer cell biology including proliferation, migration, and invasion mechanisms relevant to malignant pleural disease.